Floatz logo

CANDESARTAN

Alcoholic Liver Disease

Yonsei UniversitySmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Alcoholic Liver Disease cohort.

Asset / SponsorPhaseRating
HUMAN FAECAL MATTER
Virginia Commonwealth University
Phase 1/2CCC
Livitol-70
Composite Interceptive Med Science
N/ANR

Same molecule, other indications

CANDESARTAN is also rated in:

hypertensive disorderDormant
BB
Indicative ·
71 / 100
View asset →
stroke disorderDormant
BB
Indicative ·
68 / 100
View asset →
cardiovascular disorderDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →